Image 1 of 4
Image 2 of 4
Image 3 of 4
Image 4 of 4
Packaging & supply options
Your format, your way.
The same research peptide, with a choice of accessories and supply formats. Here’s what each option includes.
BAC water
Vial kit
Lyophilised peptide vial with separately packaged, complimentary BAC water.
BAC water + syringes
Syringe kit
Lyophilised peptide vial, BAC water and syringes.
BAC water + pen
Injection pen kit
Lyophilised peptide vial, BAC water and an injection pen.
Pen + pen needles
Reconstituted pen
VIETNAM ONLYPeptide solution supplied in a pen at the stated concentration, with pen needles.
For laboratory research only. Not for human or veterinary use.
Everform Pharma · Compound profile
CJC 1295.
The signal, explored.
A closer look at the form without DAC, growth hormone signalling and the importance of molecular identity.
What is CJC 1295 (without DAC)?
CJC 1295 (without DAC) is a research-market name commonly used for modified GRF (1–29), a synthetic analogue of growth hormone-releasing hormone (GHRH). It belongs to a family of peptides investigated for signalling at the pituitary and the release of growth hormone.
The words “without DAC” matter. The CJC-1295 developed in the original pharmacology programme included an albumin-binding modification designed to prolong its presence in circulation. The product described here is labelled without that modification. [1]
Names alone do not confirm molecular identity. A published analytical investigation identified a 29-amino-acid, amidated peptide in a preparation marketed as CJC-1295, illustrating why the precise compound and its documentation deserve attention. [4]
How it works
GHRH provides a signal to growth-hormone-producing cells in the anterior pituitary. Modified GRF analogues are designed around the biologically active region of that signalling peptide. In the original CJC-1295 development work, related albumin conjugates stimulated growth hormone release in cultured rat pituitary cells. [1]
DAC means drug affinity complex. In the studied long-acting compound, a reactive extension enabled binding to circulating albumin. Removing this feature changes the molecule; the long persistence reported for DAC-containing CJC-1295 cannot simply be assigned to a product without DAC. [1]
PITUITARY SIGNALLING
Research into GHRH-related stimulation of growth hormone release.
MOLECULAR DESIGN
Examining how structural changes and albumin binding affect a peptide’s behaviour.
Main research areas
The literature offers useful context for this peptide family. Each study must be read with the exact compound in mind.
| Research area | What the evidence addresses |
|---|---|
| Growth hormone release | Cell and rat experiments with albumin-binding GHRH analogues, rather than direct clinical validation of the product without DAC. [1] |
| GH and IGF-I | Hormone measurements in healthy adults given long-acting CJC-1295 with DAC. [2] |
| Hormone rhythm | Overnight sampling of GH secretion following the DAC-containing analogue. [3] |
| Peptide identification | Mass-spectrometric characterisation of a 29-amino-acid preparation marketed as CJC-1295. [4] |
These studies concern molecular identity and endocrine biology. They do not establish muscle gain, fat loss, better sleep or improved recovery from this Everform product.
What published findings show
Laboratory and animal development: Jetté and colleagues investigated GHRH analogues that bind albumin. Their cell and rat experiments supported development of the long-acting DAC compound. They do not establish the duration or clinical effects of the corresponding form without DAC. [1]
Human hormone measurements: Teichman and colleagues studied long-acting CJC-1295 in healthy adults and reported sustained increases in GH and IGF-I. These findings apply to the DAC-containing investigational molecule, not automatically to modified GRF without DAC. [2]
Pulsatility: Ionescu and Frohman observed preserved GH pulses alongside increased trough and mean GH levels after the long-acting analogue. This finding also shows why the simplified claim that DAC necessarily eliminates pulses is misleading. It does not demonstrate a particular pulse pattern for the product without DAC. [3]
Analytical identification: Henninge and colleagues used high-resolution tandem mass spectrometry to characterise a marketed preparation. This was an identification study, not a trial of benefits or safety. [4]
The primary studies cited here do not directly establish clinical benefit or safety for this standalone CJC 1295 (without DAC) product. Hormone changes are not, by themselves, evidence of improved strength, body composition or longevity.
The Everform product, at a glance
Compound labelCJC 1295 (without DAC)
Labelled vial amount20 mg
Base formatLyophilised peptide powder
Supply optionsSee the format guide above
Everform Pharma is based in Da Nang, Vietnam. This profile describes the standalone product without DAC. Select an available supply format using the product options above. Complimentary BAC water is included with every order.
Explore Your format, your way →
Check the full REF on the product against the relevant documentation. The security sticker repeats that product identifier and should match the vial or pen; it is not a separate new ID. Follow the storage conditions and expiry information on the actual label.
A COA should be read for what it measures. Identity, chromatographic purity and measured peptide content are distinct results; a purity percentage alone does not confirm the amount per vial or establish the exact molecular structure.
Common questions
Is this the same as long-acting CJC-1295 with DAC?
No. The product is labelled without DAC. The albumin-binding modification was central to the long-acting compound studied in the original development programme. [1]
What does modified GRF (1–29) mean?
It describes a modified analogue based on the first 29 amino acids of growth hormone-releasing factor. Research-market terminology can vary, so the exact identity should be checked against documentation.
Is Ipamorelin included?
No. This page describes standalone CJC 1295 (without DAC), not a combination product.
Does 20 mg mean a recommended dose?
No. It is the labelled peptide amount in the vial, not a dose or an administration instruction.
Can the human DAC studies establish benefits for this product?
No. They provide context about a related molecule. Differences in molecular structure mean that its duration, hormone effects and clinical findings cannot simply be transferred to the form without DAC.
Where should I check the product identifier?
Match the full REF on the vial or pen with the package security sticker and the relevant documentation. The sticker repeats the identifier rather than creating another one.
References
Everform Pharma · Da Nang, Vietnam
Educational product information.
For laboratory research only.
Not for human or veterinary use.
